Insulin Receptor

Related Products

Insulin receptor (IR), a phylogenetically ancient tyrosine kinase receptor, is a large cell surface glycoprotein that concentrates insulin at the site of action and also initiates responses to insulin. The receptor is a disulfide-linked oligomer comprised of two alpha and two beta subunits. The insulin receptor exists in two isoforms, IR-A and IR-B, expressed in different relative abundance in the various organs and tissues. The two IR isoforms have similar binding affinity for insulin but different affinity for insulin-like growth factor (IGF)-2 and proinsulin, which are bound by IR-A but not IR-B.

The insulin receptor has a crucial role in controlling glucose homeostasis, regulating lipid, protein and carbohydrate metabolism, and modulating brain neurotransmitter levels. Insulin receptor dysfunction has been associated with many diseases, including diabetes, cancer and Alzheimer's disease.

Insulin Receptor Related Products (187)
Recombinant Proteins (8)
Antibodies (8)

By Effects:	Inhibitors (59) Agonists (31) Substrates (3) Ligand (1) Antagonists (12) Activators (30) Modulators (4) Inducer (1)

Cat. No.	Product Name	Effect	Purity	Chemical Structure

HY-P11271A

Ribupatide TFA	Agonist	99.75%
Ribupatide TFA is a dual gastric inhibitory polypeptide (GIP) and glucagon-like peptide 1 (GLP-1) receptor agonist. Ribupatide TFA can be studied in antidiabetic research.

HY-114118S

Semaglutide-d₈		99.88%
Semaglutide-d₈ is the deuterium labeled Semaglutide (HY-114118). Semaglutide is a long-acting, selective, competitive GLP-1R agonist that can penetrate the blood-brain barrier. After activating GLP-1R, Semaglutide promotes insulin secretion, inhibits gastric emptying and appetite, and at the same time enhances autophagy, inhibits oxidative stress and apoptosis. Semaglutide also regulates mitochondrial function and lipid metabolism (such as reducing de novo lipogenesis in the liver). Semaglutide has activities such as lowering blood sugar, reducing weight, neuroprotection (such as improving motor function in Parkinson's disease models, reducing α-synuclein aggregation) and improving hepatic steatosis. Semaglutide can be used for the study of neurodegenerative diseases and liver diseases such as type 2 diabetes, obesity, Parkinson's disease, metabolic associated fatty liver disease (MASLD), and cancer.

HY-P990712

Ersodetug	Inhibitor	99.33%
Ersodetug is an anti-INSR (insulin receptor) human IgG2 κ monoclonal antibody. Recommend Isotype Controls: Human IgG2 kappa, Isotype Control (HY-P99002).

HY-P991290

IRAB-B	Antagonist	98.30%
IRAB-B is a human monoclonal antibody targeting INSR. IRAB-B is an insulin receptor (IR) antagonist and can be used in the study of insulin resistance and diabetes.

HY-P1878

Proinsulin C-Peptide (55-89), human		98.38%
Proinsulin C-Peptide (55-89), human is a peptide fragment of the cleavage product of proinsulin.

HY-114118S1

Semaglutide-d₈ tetraTFA	Activator	99.87%
Semaglutide-d₈ tetraTFA is the deuterium labeled Semaglutide (HY-114118). Semaglutide is a long-acting, selective, competitive GLP-1R agonist that can penetrate the blood-brain barrier. After activating GLP-1R, Semaglutide promotes insulin secretion, inhibits gastric emptying and appetite, and at the same time enhances autophagy, inhibits oxidative stress and apoptosis. Semaglutide also regulates mitochondrial function and lipid metabolism (such as reducing de novo lipogenesis in the liver). Semaglutide has activities such as lowering blood sugar, reducing weight, neuroprotection (such as improving motor function in Parkinson's disease models, reducing α-synuclein aggregation) and improving hepatic steatosis. Semaglutide can be used for the study of neurodegenerative diseases and liver diseases such as type 2 diabetes, obesity, Parkinson's disease, metabolic associated fatty liver disease (MASLD), and cancer.

HY-115461

MID-1	Inhibitor	99.36%
MID-1 is a disruptor of MG53-IRS-1 (Mitsugumin 53-insulin receptor substrate-1) interaction. MID-1 disrupts molecular association of MG53 with IRS-1 and abolishes MG53-induced IRS-1 ubiquitination and degradation in skeletal muscle, leading to elevated IRS-1 expression level and increased insulin signaling and glucose uptake.

HY-164368

GLUT4 activator 2	Activator
GLUT4 activator 2 (C59) is an insulin sensitizer, which can be used for research of diabetic diseases. GLUT4 activator 2 improves glucose uptake and insulin sensitivity in rodents. GLUT4 activator 2 interacts with Unc119 and Unc119B resulting in increased insulin sensitivity and GLUT4 translocation.

HY-P3580A

Acetyl Gastric Inhibitory Peptide (human) TFA		99.70%
Acetyl Gastric Inhibitory Peptide (human) TFA is a fatty acid derivatized analog of glucose-dependent insulinotropic polypeptide with improved antihyperglycaemic and insulinotropic properties. Acetyl Gastric Inhibitory Peptide (human) TFA can be used for research of diabetes, insulin resistance and obesity.

HY-112720

AGL-2263	Inhibitor	98.31%
AGL-2263 is an insulin receptor and insulin-like growth factor (IGF) receptor inhibitor.

HY-107207

Kaempferol 3-neohesperidoside	Activator	99.68%
Kaempferol 3-neohesperidoside (Kaempferol 3-O-neohesperidoside) is a flavonoid. Kaempferol 3-neohesperidoside mimics insulin action via the PI3K/PKC pathway, significantly promoting glucose uptake and increasing muscle glycogen content in rat soleus muscles. Kaempferol 3-neohesperidoside also exhibits anti-glycation activity. Kaempferol 3-neohesperidoside binds to albumin through hydrogen bonding and hydrophobic interactions, and inhibits the formation of advanced glycation end products. Kaempferol 3-neohesperidoside can be used in studies of diabetes and its related complications.

HY-131514

L-Ornithine 2-oxoglutarate	Activator
L-Ornithine 2-oxoglutarate (Ornithine alpha-ketoglutarate) is a nutritional compound that is a salt of amino acids with antioxidant and anti-inflammatory effects. L-Ornithine 2-oxoglutarate stimulates the production of insulin and growth hormone, and promotes intracellular amino acid transport and protein synthesis.

HY-P99530

Valanafusp alfa		98.42%
Valanafusp alfa (AGT-181) is a chimeric monoclonal antibody that fuses human α-L-iduronidase (IDUA) and targets the human insulin receptor (HIR). Valanafusp alfa has brain penetrating properties, making it useful for research on mucopolysaccharidosis type I (MPS I).

HY-15481

KU14R	Antagonist	98.91%
KU14R is a new I(3)-R antagonist, which selectively blocks the insulin secretory response to imidazolines.

HY-109530

Insulin lispro
Insulin lispro is a recombinant human insulin analogue and is one of three rapid-acting insulin analogues available. Insulin lispro can be used for the research of hyperglycaemia in diabetes mellitus.

HY-P991037

Verenafusp alfa
HY-P991037 is an INSR-targeting chimeric antibody.

HY-A0231

Glymidine sodium	Inducer	98.48%
Glymidine sodium is an oral active antidiabetic. Glymidine sodium is the inhibitor of hepatic lipolysis. Glymidine sodium inhibits the glucose formation and supresses the elevated pyruvate oxidation which results from the inhibition of endogenous lipid mobilization.

HY-P11271

Ribupatide	Agonist	98.74%
Ribupatide is a dual gastric inhibitory polypeptide (GIP) and glucagon-like peptide 1 (GLP-1) receptor agonist. Enicepatide can be studied in antidiabetic research.

HY-P10591

Olatorepatide	Inhibitor
Olatorepatide (Olatorepatidum) is a dual gastric inhibitory polypeptide (GIP) receptor and glucagon like peptide 1 (GLP-1) receptor agonist, with antidiabetic effect.

HY-146179

IMP2-IN-2	Inhibitor	99.93%
IMP2-IN-2 (compound 6) is a potent and selective IMP2 inhibitor, with IC₅₀s of 120.9 μM and 236.7 μM for IMP2 interaction with RNA_A and RNA_B, respectively. IMP2-IN-2 can be used for the research of cancer.

Name
Email *

	Sorry, but the email address you supplied was invalid.

Insulin Receptor

Insulin Receptor

Insulin Receptor Related Products (187)

Recombinant Proteins (8)

Antibodies (8)

Insulin Receptor Related Products (187):